Gastrointestinal manifestation and in-hospital mortality among end-stage renal disease patients with COVID-19: A single-center retrospective cohort study
https://doi.org/10.47895/amp.vi0.9694
- Author:
Saul B. Suaybaguio
1
;
Jade D. Jamias
2
;
Marla Vina A. Briones
3
Author Information
1. Department of Internal Medicine, Section of Gastroenterology, East Avenue Medical Center, Diliman, Quezon City, Philippines
2. Liver Center, Internal Medicine Department, National Kidney and Transplant Institute, Diliman, Quezon City, Philippines
3. Naga City, Camarines Sur, Philippines
- Publication Type:Journal Article
- Keywords:
digestive symptoms
- MeSH:
Kidney Diseases;
SARS-CoV-2
- From:
Acta Medica Philippina
2024;58(Early Access 2024):1-7
- CountryPhilippines
- Language:English
-
Abstract:
Background and Objective:Gastrointestinal (GI) manifestations among COVID-19 patients are common; however, their relation with patient outcomes remains unclear. The study, therefore, aims to determine the association of GI manifestation with in-hospital mortality among end-stage renal disease patients (ESRD).
Methods:This is a retrospective cohort design. All 501 ESRD patients with COVID-19 and admitted to the National Kidney and Transplant Institute from June 2020 to 2021 were included. GI manifestation was defined as the presence of any of the following signs and symptoms on admission: dysgeusia, anorexia, abdominal pain, nausea, vomiting, diarrhea, and jaundice. The outcome of interest was in hospital mortality, defined as death due to any cause during hospital stay. Stata17 was used for data analysis.
Results:The overall prevalence of GI manifestation was 58.08% (95% CI: 53.63-62.45). The most common symptoms were abdominal pain (27.15%), loss of appetite (24.35%), and nausea (19.76%). Patients with GI manifestation had a higher proportion of stroke, lower median systolic blood pressure, and a lower proportion of abnormal oxygen saturation and diastolic blood pressure than those without GI manifestation. Across all clinical outcomes, only hospital stay significantly differ between those with and without GI manifestation. In-hospital mortality was 31.14% (95% CI: 27.10-35.39%) and showed no significant association with GI manifestation (OR= 0.94, p=0.749).
Conclusions:GI manifestation was common among ESRD patients with moderate-to-severe COVID-19. The inhospital mortality rate is also high; however, GI manifestation was not associated with this outcome. Meanwhile, GI manifestation leads to longer hospital stay.
- Full text:20240923000018086302.pdf
